Plandai Biotechnology Reports Positive Human Clinical Trial Results on New Topical Cream

Publishing & Media

Share Tweet

Plandai Biotechnology Reports Positive Human Clinical Trial Results on New Topical Cream

Plandai Biotechnology Inc.'s (OTCQB: PLPL), a company that develops heath products from cannabis plant extracts, reported favorable results from a recent human clinical trial involving a topical preparation of its Phytofare(TM) Catechin Complex.

Trial Results

In a Mar. 20 press release, the Seattle/Australian-based company reported on the study, which was undertaken by Prof. Banie Boneschans, North West University in Potchefstroom, South Africa. It was a double-blind study that tested the anti-aging properties of Phytofare. Specifically, the trial tested surface parameters (scaling and roughness), skin hydration, and skin elasticity.

The results stated that Phytofare yielded "statistically significant" results when compared to a baseline product. The trial involved 35 female Caucasian test subjects who applied two topical creams daily, the only difference being that one contained Phytofare(TM), to skin patches which were tested at 14, 28, and 42 days.

The process of aging has a direct impact on the status of the skin surface. Skin imperfections, such as wrinkles and scaliness, reflect light differently than smooth, younger skin. A UVA-light camera with a black-and-white video sensor was used to photograph the skin surface and then measured the differences in texture. The study showed that the addition of Phytofare(TM) improved skin roughness by as much as 15% at 28 days, and a reduction in scaliness of the stratum corneum by 20%. Both of these measures were deemed "statistically significant" by the researcher.

Find out what could be the best investor’s move when it comes to PLPL by getting the complete report here, or by cutting and pasting the following link in your Web browser:

New Products Facility

This comes only three days after Plandai experienced high trading volume fueled by the Mar. 18 announcement that has completed and successfully tested Stage 1 of its state-of-the-art production facility on the Senteeko Tea Estate in South Africa. Video of the test is available on the company’s website at Once fully commissioned, the factory will produce the company's proprietary Phytofare(TM) Catechin Complex, which is a highly bioavailable green tea extract that will be marketed to nutraceutical companies as an ingredient across a broad spectrum of health and wellness products.

The company also disclosed that Stage 2 is scheduled to be completed and tested on Mar. 21 with Stage 3 brought online in early April. The final commissioning will take place over April as the company's engineers and scientists fine-tune the equipment, train staff, and test the output for conformity with the product profile.

At capacity, the Senteeko facility can process 988 acres of live green tea, yielding a total of eight tons of Phytofare(TM) every month. The facility is designed to also process lemons, which will be used to produce a Limonoid Glycoside Complex. Most of the citrus line equipment has been delivered, though this segment of the facility will not be brought online until later in 2014, pending the completion of additional clinical trials.

On Mar. 21, the share value of PLPL closed at $1.19, down 15 cents from $1.10, the previous day's close, on volume of 564,971 shares.

Find out what could be the best investor’s move when it comes to PLPL by getting the complete report here, or by cutting and pasting the following link in your Web browser:

Tranzbyte Corp. Forms Partnership with Abattis

Tranzbyte Corp. (OTCPINK: ERBB) stock volume soared Mar. 21, with 234,237,797 shares changing hands, significantly higher than its three-month average volume of 205,333,100 shares.

The surge in volume is being triggered in part by the Tempe, Ariz.-based medical marijuana dispensary company’s Mar. 21 announcement  that it signed a Letter of Intent to form a strategic partnership with Abattis (OTC Pink: ATTBF) .

Under terms of the agreement, the companies will sell and market or otherwise license one another's products in their respective regions. Once the arrangement is completed, Tranzbyte will have access to Abattis' expanding suite of bio-ceutical grow products found in the Biocube Green Grow Systems for cultivation (LED's, Nutrients - Natures Juice).

In addition, Abattis owns proprietary flash freeze extraction technology, which produces high-grade cannabis and other botanical extracts. Conversely, Abattis will have the Canadian rights to distribute ZaZZ(TM) and will pair Tranzbyte's Jurassic O2 water systems with its Biocube Green Grow Systems sales efforts in the US.

"When one looks at the obvious NAFTA synergy, this relationship makes all the sense in the world. Abattis is a powerhouse in Canada; we are stronger in the United States," Tranzbyte COO Stephen Shearin, said in a written statement.

Technology That Speeds Up Growth of Marijuana

This latest good news comes only a few weeks after Tranzbyte reported that it was testing a new gas/watering system that dramatically increases the parts per million of oxygen in water and has several benefits including speeding up the growth of marijuana and increasing its yield.

The company executed a Letter of Intent on Feb. 12, 2014, to license this patent-pending technology for distribution throughout the marijuana growing industry in the United States. Tranzbyte is in the process of negotiating a formal licensing agreement with the owners of the technology pending the results of the tests which began in Phoenix and California last weekend.

Speeds Growth and Repels Pests

According to Tranzbyte, the new technology re-creates atmospheric conditions similar to those of prehistoric times.

"Think: the Jurassic era. Think of accomplishing the mythological 'fifth grow'. This serves to increase product availability and adds profit straight to the bottom line for the grower," says Stephen Shearin, Tranzbyte's chief operating officer. "An apparent side benefit is that several common pests associated with grow operations don't seem to favor the higher O2 environment. It was an unintended consequence of the process, but it could be as big a feature as achieving radically increased growth," he added.

On Mar. 21, ERBB share price closed at 7 cents, up 1 cent from the share price of 6 cents at the close of the previous day.

Find out what could be the best investor’s move when it comes to ERBB by getting the complete report here, or by cutting and pasting the following link in your Web browser:


mCig Inc.'s Stock Volume Surge Continues

Bellevue, Wash./Australian e-cigarette maker mCig, Inc.'s (OTCQB:MCIG) stock volume continued to soar  Mar. 21  with 4,837,905 shares changing hands. 

The surge in volume is continuing to be fueled in part the company's Mar. 7 announcement that it has achieved its first profitable quarter in its history.

Here are the details:

Third-Quarter financial Results for the Quarter Ended Jan. 31, 2014

·      First Profitable Quarter in Corporate History - Adjusted Non-GAAP Net Income of $30,256*

·      Sales of $85,109 Reflect Only 24 Inventory Days Due to Chinese New Year and Overwhelming Demand

Significant Balance Sheet Improvement

·      Shareholder Equity Increase to $1,321,736 compared to negative ($210,087) for the quarter ended January 31, 2013

·      Debt, Financial Debt, and Interrelated Party Loans Reduced to Zero

Completion of Vapolution, Inc. Acquisitions Marking Entrance to Traditional Home-Use Vaporizers

mCig, Inc. (OTCQB:MCIG) is pleased to report the results of its first operational quarter since launching the mCig 1.0 in November 15, 2013 and the mCig 2.0 on January 14, 2014.

Due to a combination of factors including: Overwhelming demand for the mCig 1.0, the subsequent decision by management mid-quarter to halt 1.0 production in favor of fast-tracking production and launch of mCig 2.0, and the Chinese New Year affecting resupply of the mCig 2.0 following launch, management would like to qualify that all sales and income figures reported for the period ended January 31, 2014 reflect a total of just 24 inventory days:

·      10 Inventory Days for the mCig 1.0

·      14 Inventory Days for the mCig 2.0

Financial Results

Notwithstanding these supply issues, the company is pleased to report over $85,000 in revenue reflecting an increase of over 580% over the same quarter in 2013.

Gross Profit was $54,474 reflecting a gross profit margin of 64%. Due to disciplined cost controls the company is pleased to report US GAAP Net Income of $10,804 reflecting a net income margin of 12.7%. *Non-GAAP Adjusted Net Income calculated by excluding non-cash items such as share-based compensation and amortization was $30,256 or 35.6% of revenues.

Significant Balance Sheet Improvement

Total Shareholder Equity rose to $1,321,736 from a shareholder deficiency of ($210,087) during the same quarter in 2013. Total debt has been retired with mCig carrying zero debt as January 31, 2014 down from $196,000 during the same quarter last year.

On Mar. 21, MCIG’s share price closed at 79 cents, down 5 cents from the share price of 84 cents the previous day.

Find out what could be the best investor’s move when it comes to MCIGS by getting the complete report here, or by cutting and pasting the following link in your Web browser:


ABOUT US: issues momentum alerts on stocks that can provide gains to day traders. provides members with timely information and exclusive alerts on cheap and under-valued stocks in the United States with the potential to deliver gains of 100% - 200% or more. monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities. Through a vast network of IR professionals is often in the know of several large investor awareness campaigns being deployed.

Timing is everything when trading Penny Stocks. Gain an Edge by joining the newsletter and receiving alerts from a Pro-Active team of researchers. Trading Alerts believes traders should have a chance at successfully trading penny stocks and invites traders and investors to be part of the Free VIP membership.

Simply sign up for free and start receiving exclusive alerts.

Subscribe Here:

Disclosure is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always own due diligence with any potential investment.